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Abstract
Neuroblastoma is a predominantly pediatric cancer, arising from the primordial neural 
crest cells that form the sympathetic nervous system. The prognosis for patients with 
neuroblastoma can vary from uniform survival in low risk patients to fatality in patients 
with high risk disease. This chapter gives a brief overview of the epidemiology, genetics, 
clinical presentation, diagnosis, and discussion of the various staging systems and risk 
classifications of neuroblastoma. We also briefly describe our understanding of the con-
ventional and novel treatment modalities available and their effects on the current prog-
nosis of patients with neuroblastoma. The purpose of this chapter is to serve as a brief 
overview of the clinical aspects of neuroblastoma, to serve as a foundation of knowledge 
for scientists aspiring to develop new therapeutic modalities for this dreadful pediatric 
disease.
Keywords: neuroblastoma, epidemiology, clinical presentation, diagnosis, clinical 
staging and risk stratification, prognosis, current treatment modalities, novel and 
targeted therapy
1. Introduction
Neuroblastoma is a neoplasm arising from the primordial neural crest cells that form the sym-
pathetic nervous system. It is a cancer predominantly seen in pediatric patients. It is the most 
common extracranial malignancy of childhood and the most common solid tumor of infancy 
[1]. It is one of the most enigmatic tumors with extremely heterogeneous clinical behavior that 
ranges from spontaneous regression to metastatic disease refractory to therapy. It accounts for 
about 7% of all childhood malignancies; however 10% of childhood cancer related mortality. 
Treatment approaches have been based on presence or absence of specific clinical or biologic 
factors. Although substantial progress has been made in the treatment and outcomes for low 
and intermediate risk neuroblastoma, success in therapy of high risk neuroblastoma remains 
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evasive and complicated. Patients with low and intermediate risk neuroblastoma have an 
overall survival rate exceeding 90% and are now moving toward minimization of therapy [2]. 
However in spite of standard therapy for high risk neuroblastoma patients involving multi-
agent chemotherapy induction, surgery and external beam radiotherapy, myeloablative che-
motherapy with autologous hematopoietic stem cell rescue and biologic agents, only 50% of 
patients with newly diagnosed high risk disease will survive [2].
1.1. Origin and embryology
The neural crest is an embryonic structure formed at the beginning of the 4th week of human 
development. These cells migrate to the trunk to form the sympathetic ganglia and adrenal 
medulla, however little is known about the molecular events governing the formation and 
migration of these cells.
However it is important to note that although Neuroblastoma tumors can have neural crest 
cell traits, they also share properties of extra-adrenal chromaffin cells as reviewed in [3].
1.2. Epidemiology
The incidence of neuroblastoma is 10.5 per million children between 0 and 14 years of age in 
North America and Europe. There is a slight male preponderance of 1.2:1.0 [1]. The median 
age of diagnosis for neuroblastoma in patients is 19 months (ranging from 0 to 4 years). In fact 
one study reported that 16% of infant neuroblastomas were diagnosed during the 1st month 
of life (i.e. neonatal) and 41% during the first 3 months [4]. Less than 5% of neuroblastomas 
are diagnosed at 10 years of age or older [5]. Although there are no significant geographic 
variations in the incidence, African American and Native American patients are more likely to 
have high risk disease features and poor outcomes due to genetic differences [6].
1.3. Genetics
Genetics form a major part of risk stratification, targeted treatment and prognosis markers 
for neuroblastoma. Although MYCN amplification was found as early as in 1983, the find-
ing of further genes involved in oncogenesis took much longer [7]. However, over the past 
decade this has changed significantly, due to the advances made in exome and whole-genome 
sequencing [7]. In addition to MYCN, two other oncogenes, ALK [8] and LIN28B [9] were also 
found to be amplified, although in much lower frequency.
1.4. Oncodriver genes in neuroblastoma
1.4.1. MYCN
Karyotyping on neuroblastoma was frequently found to reveal gene amplifications. The MYC 
related oncogene MYCN (2p24) was originally identified by Schwab and colleagues [10, 11] as 
a target of this amplification event. It was later found that amplification of MYCN is associated 
with advanced stages of disease, unfavorable biologic features and poor prognosis [12, 13].
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It was also found to be independently associated with poor outcome in otherwise favorable 
patient groups [14, 15]. At present, the MYCN gene status is determined routinely at diagnosis 
for therapy planning. Fluorescent in situ hybridization is the preferred technique for detec-
tion of MYCN amplification. Most groups define amplification as >4 times the number of 
MYCN copies as compared to a control probe. In most tumors with MYCN amplification, the 
copy number is often as high as 50–400 copies/cell. MYCN amplification has been found to be 
a mutation present at diagnosis and not one that is acquired with tumor progression. MYCN 
is a member of the proto-oncogene family and is responsible for expression of approximately 
15% of all human genes. Hence overexpression causes a significant impact on cell behaviors.
1.4.2. ALK
The developing nervous system has been found to express a cell surface receptor tyrosine 
kinase controlled by the ALK (Anaplastic Lymphoma Kinase) gene [16]. Germline ALK muta-
tions are the major cause of hereditary neuroblastoma as described below, however somati-
cally acquired ALK-activating mutations are also found as oncogenic drivers in 8–10% of 
sporadic neuroblastoma [16]. In combination with tumors that also exhibit MYCN amplifi-
cation, 10–14% of neuroblastoma tumors have an ALK alteration that may serve as a novel 
therapeutic target. Crizotinib (one of the first ALK inhibitors) is currently being tested in neu-
roblastoma [17].
1.5. Hereditary predisposition to neuroblastoma and associated syndromes
The incidence of familial neuroblastoma is estimated to be 1–2% [1]. It is very unusual for an 
individual neuroblastoma patient to have a family history positive for neuroblastoma [18]. 
Analysis of rare family pedigree charts, are strongly supportive of an autosomal dominant 
inheritance with incomplete penetrance [8, 19]. Familial disease has the same diverse clini-
cal behavior as sporadic neuroblastoma, ranging from aggressive progression to spontane-
ous regression. Genetic cases most often are seen to have multifocal and/or bilateral adrenal 
primary tumors. The median age of onset for familial neuroblastoma is at around 9 months 
of age. Familial neuroblastoma patients differ from their sporadic counterparts in that they 
are diagnosed at an earlier age and/or with multiple primary tumors and are associated with 
other cancer predisposition syndromes [20–22].
Missense, nonsense and polyalanine repeat expansion mutations in PHOX2B were collectively 
found to be responsible for approximately 5% of hereditary neuroblastomas [23]. PHOX2B is 
a homeobox gene and is a key regulator of normal autonomic nervous system development 
and inactivating mutations of this gene account for this rare field defect of sympathoadrenal 
tissues.
Detailed studies involving familial pedigrees identified germ line mutations in the tyrosine 
kinase domain of the Anaplastic Lymphoma Kinase (ALK) oncogene [24]. Sporadic neuro-
blastoma tumors also can harbor ALK abnormalities in about 8–12% cases. Hence, collec-
tively, gain of function mutations in ALK or inactivating mutations of PHOX2B account for 
80–85% of hereditary neuroblastomas. Therefore genetic testing for mutations in these two 
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genes should be strongly considered in a patient who has a family history of neuroblastoma 
or has evidence of multiple primary tumors like bilateral adrenal tumors. If these mutations 
are found, these patients should be followed by appropriate genetic counseling and should 
be closely monitored as per cancer surveillance protocols. However there are still 15–20% of 
hereditary neuroblastoma cases still unaccounted for by these mutations, making it likely that 
one or more additional predisposition genes perhaps remain to be discovered.
From literature and multiple case reviews and review of family pedigree charts, it is now 
known that neuroblastoma can occur in other neural crest disorders (like Hirschsprung dis-
ease, Central Hypoventilation Syndrome and Neurofibromatosis NF1) [20]. These conditions 
have been given the collective term Neurocristopathy syndromes and can have difference 
therapeutic implications.
In addition to the Neurocristopathy syndromes, NB cases are also seen in other familial cancer 
syndromes like Beckwith-Weidemann syndrome (art2ref38), Noonan syndrome, Li-Fraumeni 
syndrome [25, 26], Fanconi anemia and other chromosomal breakage syndromes [21, 27].
2. Clinical presentation
Clinical presentation in patients with neuroblastoma varies based on the primary tumor loca-
tions which may occur anywhere along the sympathetic chain and on the extent of disease. 
The clinical presentation can be varied and is a combination of symptoms from the primary 
tumor and metastatic disease.
2.1. Localized disease
Most of the primary tumors arise in the abdomen (75%) of which a vast majority of them 
involve the adrenal gland. Frequency of adrenal tumors in older children is higher (40%) com-
pared to infants (25%), infants tend to have more cervical and thoracic tumors [18].
Patients with primary adrenal tumors may have a varying range of symptoms from being 
asymptomatic or can be associated with hypertension, abdominal pain, distension and con-
stipation. Sudden hemorrhage into the tumor may cause sudden severe abdominal pain due 
to stretching of the tumor capsule. If primary tumors arise from the organ of Zuckerkandl, 
bladder and bowel symptoms may also be seen due to direct compression.
Primary thoracic tumors may be discovered as incidental findings or can be asymptomatic. 
Higher thoracic and cervical masses can also lead to Horner’s syndrome (associated with 
unilateral ptosis, miosis and anhidrosis), superior vena cava syndrome or respiratory distress 
due to pressure on surrounding structures.
Paraspinal tumors can also have epidural or intradural extension and can cause symptoms 
from compression of nerve roots and spinal cord. These symptoms can include paraplegia, 
bladder or bowel dysfunction or radicular nerve pain. Spinal cord compression can become a 
medical emergency in some patients with neuroblastoma (Table 1).
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2.2. Metastatic disease
Approximately half of the patients present with metastasis. Metastasis can be lymphatic or 
hematogenous. Distant metastatic sites include cortex of bones, bone marrow, liver and non-
contiguous lymph nodes. Neuroblastoma usually spreads to metaphyseal, skull and orbital 
bones. This can hence lead to symptoms of periorbital ecchymosis (raccoon eyes), proptosis 
and visual impairment. Children with metastatic tumors can be quite ill appearing at pre-
sentation as opposed to the relative benign nature of presentation of children with localized 
disease and can have fever, generalized body pain (due to bony metastases), weight loss and 
irritability. Other sites of distant metastasis can be in the lungs or intracranial. Clinical syn-
dromes or paraneoplastic syndromes known to be associated with the presentation of neuro-
blastoma are summarized in Table 2.
2.3. Stage 4S neuroblastoma
The strikingly different phenotype of neuroblastoma is called 4S (S: special). It is a unique 
presentation of neuroblastoma seen in infants. This is seen to occur in about 5% cases of neu-
roblastoma [18]. These infants usually have small localized primary tumors; however have 
diffuse metastatic involvement at presentation. Metastatic sites can include diffuse involve-
ment of liver, hepatomegaly, sometimes significant enough to cause respiratory compromise, 
diffuse subcutaneous nodules due to metastasis to skin, metastases to the bone marrow.
2.4. Paraneoplastic syndromes
There are two well described, but rare paraneoplastic syndromes associated with neuro-
blastoma, secretory diarrhea (due to production of vasoactive intestinal peptide from the 
tumor) and opsoclonus myoclonus ataxia syndrome (OMS). OMS consists of opsoclonus 
Location of tumor or area of metastatic 
involvement
Signs and symptoms
Abdomen/pelvis Distension, constipation, urinary retention, pain, hypertension (due to 
renal vein compression)
Thorax Respiratory distress, superior vena cava syndrome, Horner’s syndrome
Neck Swelling
Presacral/paraspinal tumors Urinary retention, paraplegia/paresis, clonus
Metastases Bone pain, irritability, cytopenias (anemia causing pallor, petechiae), 
periorbital ecchymoses, weight loss, fever
4S/4M metastases Hepatomegaly, hyperbilirubinemia, coagulopathy, bluish skin nodules, 
respiratory distress due to abdominal distension
Paraneoplastic syndromes VIP secreting tumors: intractable diarrhea  
OMS: myoclonic jerking and random eye movements
Table 1. Neuroblastoma symptomatology.
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(conjugate, multidirectional, chaotic eye movements), myoclonus (non-epileptic limb jerk-
ing) and ataxia (loss of balance). Between 1 and 3% of patients with neuroblastoma can 
have OMS [28, 29]. In most patients, the syndrome itself leads to the diagnosis of neuroblas-
toma; however it may rarely occur after tumor resection or even at relapse. In at least half of 
the children affected, OMS is associated with underlying occult or clinically apparent neur 
oblastoma. Hence, a thorough diagnostic evaluation for neuroblastoma at presentation is 
necessary in all patients with OMS, after exclusion of central nervous system pathology. A 
few previously reported series [28, 30, 31] show that 90% of patients presenting with OMS 
were without metastases at diagnosis, compared to 40–50% with metastases in non-OMS 
patients. OMS is thought to be due to an antineural antibody that cross-reacts with the anti-
gen on both neuroblastoma and the normal nervous system tissue. Tumor biology, includ-
ing MYCN copy number and Shimada histopathologic classification are usually favorable in 
OMS patients, which correlates with the excellent survival rate found in patients with OMS 
and neuroblastoma [28].
Treatment has been documented with various agents including glucocorticoids, adre-
nocorticotrophic hormone and intravenous immunoglobulin [29]. However almost 80% 
of patients will experience relapse of symptoms with weaning of treatment measures or 
with a viral syndrome. OMS can also be associated with long term chronic neurological 
complications.
Treatment resistant secretory diarrhea is seen in approximately 4% of patients with neuro-
blastoma and thought to be due to overproduction of vasoactive intestinal peptide (VIP) by 
maturing neuroblastoma cells [32, 33]. It is associated with chronic watery diarrhea and fail-
ure to thrive. It usually resolves after surgical removal of the primary tumor.
Eponym Features associated with syndrome
Pepper syndrome Involvement of the liver with metastatic disease with or without respiratory distress
Horner syndrome Unilateral ptosis, myosis, and anhydrosis associated with a thoracic or cervical 
primary tumor. Symptoms tend to persist following tumor resection
Hutchinson syndrome Limping and irritability in young child seen with bone and bone marrow metastases
Opsoclonus mycoclonus 
ataxia syndrome
Random eye movement and myoclonic jerking in the presence or absence of 
cerebellar ataxia. Usually associated with a biologically favorable and differentiated 
tumor. The condition is thought to be immune mediated. It may not resolve with 
tumor removal, and exhibits progressive neuropsychological sequelae
Kerner-Morrison syndrome Intractable secretory diarrhea due to tumor secretion of vasointestinal peptides
Neurocristopathy syndrome Neuroblastoma associated with other neural crest disorders, including congenital 
hypoventilation syndrome or Hirshprung disease. Germline mutations in the paired 
homeobox gene PHOX2B have been identified in a subset of such patients
Adapted from Ref. [57]. For references, please refer to text.
Table 2. Syndromes associated with neuroblastoma.
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3. Diagnosis
3.1. Diagnostic criteria
Diagnosis of neuroblastoma is most commonly established from histopathologic evaluation 
of the primary tumor tissue. Most cases can be differentiated based on hematoxylin and eosin 
staining especially if features of neuronal differentiation are present. In case of minimal differ-
entiation, immunohistochemical staining for neuron-specific enolase, chromogranin A and/or 
synaptophysin are used.
Diagnosis of neuroblastoma can also be established by a combination of tumor cells detected 
in the bone marrow and elevated catecholamines or their metabolites [vanillylmandelic 
acid (VMA), homovanillic acid (HVA) and dopamine]. Urinary VMA and HVA should both 
be measured for diagnostic purposes and for undifferentiated tumors dopamine may be 
measured.
3.2. Clinical disease assessment
Clinical evaluation of disease includes cross-sectional imaging of the primary tumor by mag-
netic resonance imaging (MRI) or computed tomography (CT). This imaging determines the 
size of the primary tumor, regional extent of the disease, distant metastatic spread to neck, 
chest, abdomen and pelvis. Bilateral bone marrow biopsies are required to assess for presence 
of tumor cells in the bone marrow. Radioiodine labeled metaiodobenzylguanidine (MIBG) 
is a nonrepinephrine analog that selectively concentrates in sympathetic nervous tissues. It 
can be used to detect primary tumor as well as detect occult soft tissue disease in addition to 
osteomedullary disease [34]. In the scenario that MIBG is unavailable, technetium bone scan 
can also be used to detect bony metastases (however is not as sensitive or specific as MIBG). 
Bone scan or FDG-PET scan are used to assess metastatic disease in patients whose tumors 
are not MIBG avid.
4. Staging and risk stratification
4.1. Staging
Until recently, the criteria for staging at diagnosis were based on the International 
Neuroblastoma Staging System (INSS) as shown in Table 3 [35]. INSS stages 1–3 have local-
ized tumors classified based on the amount of resection, invasion and nodal involvement. 
Stage 4 is defined as distant metastases; 4S is characterized by metastases to the liver, skin, 
and/or marrow in infants and is usually associated with favorable biological features and can 
undergo spontaneous regression.
In 2009, the International Neuroblastoma Risk Group’s (INRG) stratification system was 
developed by a major consortium of North America, Europe, Japan, and Australia. The INRG 
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staging system is based on imaging criteria and the extent of locoregional disease is deter-
mined by the presence or absence of image-defined risk factors. And the extent of locoregional 
disease is determined by the presence or absence of image-defined risk factors [36] as shown 
in Table 4.
4.2. Risk stratification
Neuroblastoma is classified into low risk, intermediate risk, and high risk based on multiple 
factors including clinical and biological factors that have been shown to predict prognosis and 
the risk of recurrence. These factors include age, stage, histology, DNA index, and MYCN 
amplification (MYCNA) and are used to assign treatment groups by the Children’s Oncology 
Group [1]. The INRG developed classification system defines similar cohorts using the INRG 
database of 8800 patients treated between 1990 and 2002. This now helps facilitate compari-
sons across international clinical trials (Table 5) [37].
4.2.1. Prognostic variables of neuroblastoma
Multiple variables are used for risk prediction and as prognostic markers of neuroblastoma. The 
most commonly used prognostic markers used in all cooperative groups are discussed here.
Stage: Stage of the disease using the INSS system has been correlated with patient outcome 
and used by all cooperative groups to risk stratify. Most patients with INSS stage 1 are cured by 
surgery alone, and most patients with stage 4 require highly intensive, multimodality therapy. 
Stage Description of disease and extension
1 Localized tumor with complete gross excision, with or without microscopic residual disease representative 
ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and removed with the 
primary tumor may be positive)
2A Localized tumor with incomplete gross resection; representative ipsilateral nonadherent lymph nodes 
negative for tumor microscopically
2B Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes 
positive for tumor; enlarged contralateral lymph nodes must be negative microscopically
3 Unresectable unilateral tumor infiltrating across the midline*, with or without regional lymph node 
involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline 
tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement
4 Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or 
other organs (except as defined for stage 4S)
4S Localized primary tumor (as defined for stage 1, 2A or 2B) with dissemination limited to skin, liver, and/or 
bone marrow# (limited to infants <1 year of age)
*The midline is the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or 
beyond the opposite side of the vertebral column.
#Marrow involvement in 4S should be minimal (<10% of total nucleated cells identified as malignant on bone marrow 
aspirate or biopsy). More extensive marrow involvement is stage 4.
Data adapted from Ref. [58].
Table 3. International Neuroblastoma Risk Group Staging System (INSS).
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For the stages in between, therapy is based on other biologic factors. As the genetic and biologic 
characteristics of neuroblastoma are better defined, we will likely rely more on them and less 
on the disease stage or histology.
Stage Description
L1 Localized tumor not involving vital structures as defined by the list of image-defined risk factors and 
confined to one body compartment
L2 Locoregional tumor with presence of one or more IDRFs
M Distant metastatic disease (except stage MS)
MS Metastatic disease in children younger than 18 mo. with metastases confined to skin, liver, and/or bone 
marrow
Data adapted from Ref. [59].
Table 5. International risk group staging system (INRGSS).
Ipsilateral tumor extension within two body compartments
Neck-chest, chest-abdomen, abdomen-pelvis
Neck
Encases carotid and/or vertebral artery and/or internal jugular vein; extends to skull base; compresses trachea
Cervicothoracic junction
Encases brachial plexus roots or subclavian vessels and/or vertebral or carotid artery; compresses trachea
Thorax
Encases the aorta and/or major branches; compresses trachea and/or principal bronchi; lower mediastinal tumor 
infiltrating costovertebral junction between T9 and 12
Thoracoabdominal
Encases the aorta and/or vena cava
Abdomen/pelvis
Infiltrates the porta hepatis and/or the hepatoduodenal ligament; encases branches of the superior mesenteric artery 
at the mesenteric root or origin of celiac axis and/or superior mesenteric artery; invades one or both renal pedicles; 
encases aorta and/or vena cava or iliac vessels, crossing sciatic notch
Intraspinal tumor extension whatever the location provided that
More than one-third of the spinal canal in the axial plane invaded and/or the perimedullary leptomeningeal spaces 
not visible and/or the spinal cord signal abnormal
Infiltration of adjacent organs/structures
Pericardium, diaphragm, kidney, liver, duodeno-pancreatic block, and mesentery 
IDRFs are used to determine the ability to completely resect locoregional tumors at diagnosis based on surgical risk 
factors that can be defined by IDRFs detected on cross-sectional imaging with CT and/or MRI
Data adapted from Ref. [59].
Table 4. Image defined risk factors.
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Age: Age was one of the first and most important prognostic factors identified. Patients 
younger than 18 months of age have a much better prognosis compared to the older patients 
[38, 39], especially for patients between 12 and 18 months of age with biologically favorable 
disease. Older children, adolescents and young adults have a more indolent course and far 
worse outcomes [40].
Pathology: Shimada proposed a histology-based classification of tumors into “favorable” and 
“unfavorable” by combining age with extent of tumor differentiation, Schwannian compo-
nents in tumor and degree of mitosis [1].
Biologic factors: Current risk stratification for neuroblastoma includes MYCN copies by fluo-
rescent in situ hybridization, DNA ploidy by flow cytometry and tumor histology. MYCNA 
(MYCN amplification) is defined as greater than 10 copies and is detected in almost 20% of 
neuroblastoma tumors with a higher incidence in INSS stages 3 and 4, but only 5% of stages 
INRG 
stage
Age 
(months)
Histology Grade of tumor 
differentiation
MYCN 11q 
aberration
Ploidy Pretreatment risk 
group
L1/L2 GN maturing, 
GNB intermixed
Very low
L1 Any, except GN 
maturing or
GNB intermixed
Very low
High
L2 <18 M
>=18M
Any, except GN 
maturing or
GNB intermixed
GNB nodular 
neuroblastoma
Differentiating
Poorly differentiated 
or undifferentiated
NA
NA
NA
Amplified
No
Yes
No
Yes
Low
Intermediate
Low
Intermediate
Intermediate 
high
M <18
<12
12–<18
<18
>=18
NA
NA
NA
Amplified
HD
D
D
Low
Intermediate
Intermediate
High
High
MS <18 NA No
Yes
Very low
High
High
Classification schema is based on analysis of 8800 patients in the INRG database (1990–2002). Risk groups are very low 
risk (5-year event-free survival [EFS] >85%); low risk (5-year EFS >75–85%); IR (5-year EFS 50–75%); HR (5-year EFS 
<50%).
Abbreviations: GN: ganglioneuroma; GNB: ganglioneuroblastoma; INRG: International Neuroblastoma Risk Group; 
NA: not amplified; HD: hyperdiploid; D: diploid.
Adapted from Ref. [60].
Table 6. International Neuroblastoma Risk Group pretreatment classification scheme.
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1, 2 and 4S [36]. Multiple studies so far have demonstrated that patients with MYCNA have a 
significantly worse outcome [14, 15, 41].
A systematic review from a literature search of prognostic tumor markers in neuroblastoma 
was published, and reported 31 important prognostic factors each reported in five or more 
papers [42]. Meta-analysis of these markers showed that MYCN and DNA ploidy had the 
strongest prognostic impact. Most neuroblastomas have a nuclear DNA content in the diploid 
range. Tumors from patients who have lower stages of disease will often be hyperdiploid 
(DNA index > 1) or near triploid. DNA content is most significant as a prognostic marker in 
infants and patients with localized disease [1]. Other most commonly deleted chromosomal 
regions in neuroblastoma include 1p, 4p, 11q, 14q. Recurrent mutations are not frequent 
in neuroblastoma. Hence the identification of genes and signaling pathways with altered 
expression continue to be discovered and used to add additional value to prognostic factors 
and therapeutic targets involved in neuroblastoma apoptosis, drug resistance, angiogenesis, 
metastasis and inflammation [3, 43].
These factors were then combined to form a pre-treatment Risk Group Stratification as shown 
in Table 6.
5. Conventional treatment of neuroblastoma
The diagnosis and treatment of neuroblastoma is a multidisciplinary approach. Risk stratifi-
cation is the first and most important step of treatment planning. It includes surgical biopsy 
especially to assess tumor genetic and histologic features, most importantly in patients less 
than 18 months with metastatic disease.
5.1. Treatment of low and intermediate risk neuroblastoma
Patients with low- or intermediate-risk neuroblastoma have excellent outcomes, and a series 
of cooperative group trials evaluating reductions in therapy using risk-based treatment 
approaches for these children has led to decreased therapy-related toxicities and improved 
outcomes. Survival rates for patients with INSS stage 1 disease are excellent with surgery 
alone and rare recurrences can be cured easily with salvage chemotherapy [44]. Survival rate 
for these groups with surgery alone is as high as 95%. For patients with INSS stage 1, 2A, 
2B chemotherapy is reserved for patients with localized neuroblastoma with life threatening 
symptoms, or even for patients who experience recurrence or progressive disease.
Stage 4S neuroblastoma without MYCNA, undergo spontaneous regression. Chemotherapy 
or even low dose radiation can be used for large tumors causing symptoms or massive hepa-
tomegaly [45].
Patients with intermediate risk disease which includes patients with INSS stage 3 and infants 
with stage 4/M and favorable biologic features are treated with regimens using surgical resection 
and moderate dose chemotherapy as the backbone. Patients with favorable tumor characteristics 
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including infants with stage 4/M without MYCNA, the survival rates for surgery combined with 
moderate dose chemotherapy is greater than 90% [46].
5.2. Treatment of high risk neuroblastoma
Current treatment strategies for high risk neuroblastoma consist of three phases: induction 
phase, which consists of removal of gross tumor and achieving local control. The second 
phase of consolidation is to treat remaining chemotherapy-exposed cells to achieve lowest 
possible residual disease. Post-consolidation or maintenance phase is finally for treatment of 
the minimal residual disease. A general overview of the current day standard of care treat-
ment strategy is described in Figure 1.
5.2.1. Induction therapy
Standard Children’s Oncology Group (COG) induction regimens include various combina-
tions of alkylators, anthracyclines, topoisomerase I and II inhibitors, platinum compounds 
delivered in 21 day cycles for 5–6 cycles. A successful induction which leads to complete 
remission (CR) or very good partial remission (VGPR) has been shown to correlate with 
improved overall survival. Following five cycles of induction chemotherapy, local control 
of primary tumor site is achieved with a combination of aggressive surgical resection and 
radiation therapy to the surgical bed. Surgery is performed after four to six cycles of induc-
tion chemotherapy to improve resectability and minimize surgery related complications. 
Complete tumor resection appears to correlate with improved local control and also signifi-
cantly improved event-free survival (EFS) [47].
Figure 1. Treatment strategy currently used for patients with high risk neuroblastoma. ch14.18: chimeric 14.18, mAB: 
monoclonal antibody, GMCSF: granulocyte-macrophage colony stimulating factor, IL-2: interleukin-2.
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5.2.2. Consolidation therapy
Several clinical trials performed in North America, Germany and Europe over the past 20 
years has demonstrated improved outcomes following myeloablative therapy with autolo-
gous stem cell rescue. A Cochrane systems meta-analysis review by Yalçin et al. revealed 
that myeloablative chemotherapy has improved EFS [48]. The North American groups have 
traditionally used cyclophosphamide/etoposide/Melphalan for chemotherapy, whereas the 
European group (SIOPEN) data results suggest that patients randomized to the Busulfan/
Melphalan arm had superior outcomes [49]. Another Children’s Oncology Group Study 
ANBL0532 also studied differences in outcomes between patients receiving single vs tandem 
myeloablative transplants (Figure 2) and found that 3-year event-free survival was signifi-
cantly better in the tandem group than in the single group (61.4% vs 48.4%; P = 0.0081). There 
was a nonsignificant trend toward better 3-year overall survival in the tandem group than in 
the single group before immunotherapy (74.0% vs 69.1%; P = 0.1850).
Consolidation therapy also consists of radiation to the primary site, as neuroblastoma is one 
of the most radio-sensitive pediatric tumors. Doses of 2160 cGy (centiGray) in daily 180 cGy 
fractions to the primary sites decreases local recurrence rates [50]. Radiation is also deliv-
ered to MIBG-avid metastatic sites, with a recent report suggesting that non-irradiated lesions 
have a higher risk of involvement at the time of relapse [51].
5.2.3. Post-consolidation biologic and immunotherapies
Following surgery and high dose chemotherapy followed by autologous stem cell rescue, treat-
ment with synthetic retinoid isotretinoin (cis-retinoic acid) showed significantly promising 
Figure 2. Tandem autologous stem cell transplant regimen used for patients with high risk neuroblastoma. ASCT: 
autologous stem cell transplant, ch14.18: chimeric 14.18, mAB: monoclonal antibody, GMCSF: granulocyte-macrophage 
colony stimulating factor, IL-2: interleukin-2.
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results and is hence an established as standard of care [52]. Another randomized control trial 
also demonstrated that the addition of anti-GD2 chimeric monoclonal antibody (mAB) with 
cytokines (granulocyte-macrophage colony stimulating factor and interleukin 2) improved 
survival [53]. Additional studies have also shown the benefit of immunotherapy at diagnosis 
as well as first recurrence of disease. However this regimen has multiple side effects: fever, 
allergic reactions, hypotension, pain, capillary leak syndrome.
In spite of all the therapeutic modalities explained above directed at high risk neuroblastoma, 
even-free survival for these patients is only 40–50%. In the INRG data set, overall survival 
for patients who relapse after treatment for low/intermediate risk disease was 65%, 5 years 
after recurrence, but for patients with high risk/metastatic disease, the 5-year overall survival 
was only 8% after recurrence. There is hence a real need for potential new targeted therapy 
and also alternative therapies to improve chemo-sensitivity in these patients with high risk 
neuroblastoma.
6. Novel therapeutic interventions
Relapse strategies are divided into chemotherapy, immunotherapy, MIBG/radioisotopes and 
targeted therapies. These therapies are mostly being tested in Phase I and II trials in patients 
with recurrent or relapsed neuroblastoma.
6.1. Immunotherapeutic targets
Due to the initial success of passive immunotherapy with anti-GD2 antibody chimeric 14.18 in 
high risk neuroblastoma, there has been a surge in the development of additional immunothera-
peutic modalities. Clinical trials evaluating anti-GD2 therapeutics and chemotherapy (irinote-
can plus temozolomide; COG ANBL1221) or the immunostimulatory molecule lenalidomide 
are under way. Additional pilot studies evaluating monoclonal antibody 1A7 as a surrogate 
GD2 vaccine and active immunization against GD2 and GD3 combined with the immunostimu-
lant beta-glucan in patients with complete or very good partial remission have shown encourag-
ing results. There is also increasing interest in chimeric antigen receptor expressing autologous 
T cells for cellular-based therapy in neuroblastoma [54]. In addition to chimeric T cells, infusions 
of natural killer cells, dendritic cells are also under investigation, especially in patients with 
relapsed disease.
6.2. Targeted radiotherapy
131I-mIBG (131Iodized- metaiodobenzylguanidine) is a beta particle-emitting norepinephrine 
analog which is taken up by cells expressing the norepinephrine transporter. It has been one of 
the earliest and most successful therapies for relapsed neuroblastoma. 131I-mIBG has the prop-
erties of excellent tumor targeting, the potential of delivering high levels of absorbed radiation 
to tumors in soft tissue, bone and bone marrow. It is also rapidly cleared by the kidneys, hence 
making it an ideal therapeutic agent in mIBG-avid neuroblastoma and pheochromocytoma. 
Previously, studied as an agent in patients with relapsed or refractory disease, it is now being 
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incorporated as part of induction therapy in those with mIBG-avid neuroblastoma. After years 
of being studied to establish safety and efficacy, 131I-mIBG therapies is now being studied 
in combination with other chemotherapy agents, radio sensitizers, hyperbaric oxygen, gene 
therapy or ionizing radiation from external beam radiation. A brilliant review of this subject 
is presented in the article by Streby et al. [55]. A recent Children’s Oncology Group Study is 
investigating the effects of administering 131 I-mIBG in combination with induction chemo-
therapy (in patients with mIBG sensitive tumors at diagnosis).
6.3. Molecular guided targeted therapy
Several potential molecular targets and inhibitors are now being tested especially in preclini-
cal and Phase I trials. A small subset of ALK aberrant tumors can be targeted with ALK inhibi-
tors [16]. For patients harboring MYCNA, preclinical studies are suggestive of bromodomain 
and extraterminal domain inhibitors (BET inhibitors) inducing cell death by interfering with 
MYCN transcription [56].
Other agents that target cell cycle, angiogenesis and cell differentiation are also currently 
under investigation and awaiting further preclinical and preliminary clinical studies.
Due to the variety of therapy options that are under study, it appears that most future clinical 
trials will incorporate a salient novel agent in combination with common chemotherapy as 
backbone regimens.
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